Autoimmune Pediatric CNS Disorders, Serum
Test Mnemonic
APCNSS
CPT Codes
- 86341 - QTY (1)
- 86362 - QTY (1)
- 86052 - QTY (1)
- 86255 - QTY (8)
Includes
- Purkinje Cell/Neuronal Nuclear IgG Scrn
- N-methyl-D-Aspartate Receptor Ab, Serum
- CASPR2 Ab IgG Screen by IFA, Serum
- LGI1 Ab IgG Screen by IFA, Serum
- Neuromyelitis Optica/AQP4-IgG, Serum
- GABA-B Receptor Ab IgG Screen, Serum
- MOG Antibody IgG Screen, Serum
- DPPX Ab IgG CBA IFA Screen, Serum
- GABA-AR Ab IgG CBA-IFA Screen, Serum
- mGluR1 Ab IgG CBA-IFA Screen, Serum
- Glutamic Acid Decarboxylase Antibody
Performing Laboratory
ARUP
Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 3 mL | Serum | SST (Gold) | Frozen | Separate serum from cells ASAP or within 2 hours of collection. Transfer 1.0 mL serum in three aliquot tubes and freeze. |
Minimum Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 1.5 mL | Minimum: 0.5 mL per aliquot tube |
Stability
| Environmental Condition | Description |
|---|---|
| Frozen | After separation from cells: 30 days (avoid repeated freeze/thaw cycles) |
| Refrigerated | After separation from cells: 1 week |
| Ambient | After separation from cells: 24 hours |
Days Performed
Varies
Turnaround Time
4 - 11 days
Methodology
| Name | Description |
|---|---|
| Enzyme-Linked Immunosorbent Assay (ELISA) | |
| Semi-Quantitative Cell-Based Indirect Fluorescent Antibody | |
| Semi-Quantitative Indirect Fluorescent Antibody |
Reference Range
| CASPR2 Ab IgG CBA-IFA Screen, Serum | |||||
|---|---|---|---|---|---|
| Sex | Age From | Age To | Type | Range | Range Unit |
| Less than 1:10 | |||||
| DPPX Ab IgG CBA-IFA Screen, Serum | |||||
| Sex | Age From | Age To | Type | Range | Range Unit |
| Less than 1:10 | |||||
| GABA-AR Ab IgG CBA-IFA Screen, Serum | |||||
| Sex | Age From | Age To | Type | Range | Range Unit |
| Less than 1:10 | |||||
| GABA-BR Ab IgG CBA-IFA Scrn, Ser | |||||
| Sex | Age From | Age To | Type | Range | Range Unit |
| Less than 1:10 | |||||
| Glutamic Acid Decarboxylase Antibody | |||||
| Sex | Age From | Age To | Type | Range | Range Unit |
| 0.0 - 5.0 IU/mL | |||||
| LGI1 Ab IgG CBA-IFA Screen, Serum | |||||
| Sex | Age From | Age To | Type | Range | Range Unit |
| Less than 1:10 | |||||
| mGluR1 Ab IgG CBA-IFA Screen, Serum | |||||
| Sex | Age From | Age To | Type | Range | Range Unit |
| Less than 1:10 | |||||
| MOG Ab IgG CBA-IFA Screen, Serum | |||||
| Sex | Age From | Age To | Type | Range | Range Unit |
| Less than 1:10 | |||||
| NMDA Receptor Ab IgG CBA-IFA, Serum | |||||
| Sex | Age From | Age To | Type | Range | Range Unit |
| Less than 1:10 | |||||
| NMO/AQP4 Ab IgG CBA-IFA Screen, Serum | |||||
| Sex | Age From | Age To | Type | Range | Range Unit |
| Less than 1:10 |
Special Info
Reflex Algorithm: Each reflex test performed incurs additional charge. If NMDA antibody IgG is positive, then titer will be performed. PCCA/ANNA antibody IgG is screened by IFA. If the IFA screen is indeterminate, then a Neuronal Nuclear Antibodies (Hu and Tr/DNER) IgG by Immunoblot will be performed. If the IFA screen is positive at 1:10 or greater, then a PCCA/ANNA antibodies titer and Neuronal Nuclear Antibodies (Hu and Tr/DNER) IgG by Immunoblot will be performed. If LGI1 antibody IgG is positive, then titer will be added. If CASPR2 antibody IgG is positive, then titer will be added. If AQP4/NMO antibody IgG by IFA is positive, then titer will be added. If GABA-BR antibody IgG by IFA is positive, then titer will be added. If MOG antibody IgG by IFA is positive, then titer will be added. If DPPX antibody IgG by IFA is positive, then titer will be added. If mGluR1 antibody IgG by IFA is positive, then titer will be added. If GABA-AR antibody IgG by IFA is positive, then titer will be added. Contaminated, hemolyzed, icteric, or lipemic specimens will be rejected. This test is New York state approved.
Clinical Info
Used to evaluate subacute-onset encephalopathy, epilepsy, behavior changes, or movement disorders in individuals <18 years of age.